List of Daptomycin drug patents

Daptomycin is owned by Hospira Inc.

Daptomycin contains Daptomycin.

Daptomycin has a total of 2 drug patents out of which 0 drug patents have expired.

Daptomycin was authorised for market use on 21 June, 2021.

Daptomycin is available in powder;intravenous dosage forms.

Daptomycin can be used as treatment of complicated skin and skin structure infections and staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis by administering the formulation of daptomycin as recited in claim 18, treatment of complicated skin and skin structure infections and s. aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis by reconstituting and administering the formulation as recited in claim 12.

The generics of Daptomycin are possible to be released after 11 September, 2033.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10357535 HOSPIRA INC Daptomycin formulations and uses thereof
Sep, 2033

(10 years from now)

US9655946 HOSPIRA INC Daptomycin formulations and uses thereof
Sep, 2033

(10 years from now)

Drugs and Companies using DAPTOMYCIN ingredient

Market Authorisation Date: 21 June, 2021

Treatment: Treatment of complicated skin and skin structure infections and s. aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis by reconstituting and administering the formulation as recited in claim 12; Treatment of complicated skin and skin structure infections and staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis by administering the formulation of daptomycin as recited in claim 18

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in